Richard J Caselli

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc The neuropsychology of normal aging and preclinical Alzheimer's disease
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA Electronic address
    Alzheimers Dement 10:84-92. 2014
  2. pmc Subjective cognitive decline: self and informant comparisons
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA Electronic address
    Alzheimers Dement 10:93-8. 2014
  3. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
  4. pmc Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention
    Richard J Caselli
    Department of Neurology, Mayo Clinic Phoenix, AZ 85259, USA
    J Alzheimers Dis 33:S405-16. 2013
  5. pmc Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Alzheimers Res Ther 4:20. 2012
  6. pmc Longitudinal modeling of cognitive aging and the TOMM40 effect
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Alzheimers Dement 8:490-5. 2012
  7. ncbi request reprint A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Sleep 29:927-33. 2006
  8. ncbi request reprint Alzheimer's disease a century later
    Richard J Caselli
    Department of Neurology, Mayo Clinic and Arizona Alzheimer s Disease Consortium, Scottsdale 85259, USA
    J Clin Psychiatry 67:1784-800. 2006
  9. pmc Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    N Engl J Med 361:255-63. 2009
  10. ncbi request reprint Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment
    Richard J Caselli
    Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Arch Neurol 64:1306-11. 2007

Detail Information

Publications94

  1. pmc The neuropsychology of normal aging and preclinical Alzheimer's disease
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA Electronic address
    Alzheimers Dement 10:84-92. 2014
    ..A National Institute on Aging-sponsored work group on preclinical Alzheimer's disease (AD) articulated the need to characterize cognitive differences between normal aging and preclinical AD...
  2. pmc Subjective cognitive decline: self and informant comparisons
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA Electronic address
    Alzheimers Dement 10:93-8. 2014
    ..It is unclear whether self- or informant-based subjective cognition better distinguishes emotional factors from early-stage Alzheimer's disease (AD)...
  3. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
    ..With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders...
  4. pmc Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention
    Richard J Caselli
    Department of Neurology, Mayo Clinic Phoenix, AZ 85259, USA
    J Alzheimers Dis 33:S405-16. 2013
    ....
  5. pmc Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Alzheimers Res Ther 4:20. 2012
    ..To date, this has impacted study design in some research trials but not clinical practice...
  6. pmc Longitudinal modeling of cognitive aging and the TOMM40 effect
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Alzheimers Dement 8:490-5. 2012
    ..To assess the possible contribution of TOMM40 to Alzheimer's disease onset, we compared the effects of TOMM40 and APOE genotype on preclinical longitudinal memory decline...
  7. ncbi request reprint A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Sleep 29:927-33. 2006
    ..To test the hypothesis that healthy adults reporting dream-enactment behavior (DEB+) have reduced cerebral metabolic rate for glucose (CMRgl) in regions preferentially affected in patients with dementia with Lewy bodies (DLB)...
  8. ncbi request reprint Alzheimer's disease a century later
    Richard J Caselli
    Department of Neurology, Mayo Clinic and Arizona Alzheimer s Disease Consortium, Scottsdale 85259, USA
    J Clin Psychiatry 67:1784-800. 2006
    ..To provide a current survey of the clinical and pathologic features, known genetic and suggested pathogenic contributions, diagnosis, and treatment of Alzheimer's disease (AD) and related forms of dementia...
  9. pmc Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    N Engl J Med 361:255-63. 2009
    ..The age at which memory decline diverges among persons who are homozygous for the APOE epsilon4 allele, those who are heterozygous for the allele, and noncarriers is unknown...
  10. ncbi request reprint Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment
    Richard J Caselli
    Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Arch Neurol 64:1306-11. 2007
    ..These changes could represent presymptomatic disease in some, despite their youth...
  11. doi request reprint Medical management of frontotemporal dementia
    Richard J Caselli
    Department of Neurology, Mayo Clinic and Arizona Alzheimer s Disease Consortium, Scottsdale, Arizona 85259, USA
    Am J Alzheimers Dis Other Demen 22:489-98. 2007
    ..In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout...
  12. ncbi request reprint Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment
    Richard J Caselli
    Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Arch Neurol 65:1231-6. 2008
    ....
  13. doi request reprint Creativity: an organizational schema
    Richard J Caselli
    Department of Neurology, Mayo Clinic, AZ 85259, USA
    Cogn Behav Neurol 22:143-54. 2009
    ..To describe an organizational schema of human creativity...
  14. ncbi request reprint Age-related memory decline and apolipoprotein E e4
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Discov Med 8:47-50. 2009
    ..These results correlate with imaging and neuropathological studies that show AD-like changes at this age and collectively support the existence of a presymptomatic stage of AD...
  15. pmc Amyloid load in nondemented brains correlates with APOE e4
    Richard J Caselli
    Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ 85259, United States
    Neurosci Lett 473:168-71. 2010
    ..Nondemented APOE e4 carriers over age 60 have a higher burden of total parenchymal and vascular amyloid neuropathology than NC, but no difference in neuritic plaque and NFT pathology...
  16. pmc Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes
    R J Caselli
    Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Neurology 76:1078-84. 2011
    ..To characterize the effects of cerebrovascular (CV) risk factors on preclinical memory decline in cognitively normal individuals at 3 levels of genetic risk for Alzheimer disease (AD) based on APOE genotype...
  17. pmc Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
    R J Caselli
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Neurology 76:1383-8. 2011
    ..pole/neocortex, and posterior cingulate by age 65 years in APOE ε4 carriers prior to the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), but is it impairing frontally mediated neuropsychological performance?..
  18. ncbi request reprint Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele
    R J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Neurology 62:1990-5. 2004
    ..To determine whether memory loss is detectable before the symptomatic presentation of mild cognitive impairment (MCI) in those at greater genetic risk for Alzheimer disease (AD) based upon presence or absence of the e4 allele of APOE...
  19. ncbi request reprint A distinctive interaction between chronic anxiety and problem solving in asymptomatic APOE e4 homozygotes
    Richard J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, University of Arizona, AZ, USA
    J Neuropsychiatry Clin Neurosci 16:320-9. 2004
    ..Chronic anxiety adversely affects cognitive skills in all groups, and is associated with significantly greater decline in problem solving skills in cognitively normal APOE e4 HMZ...
  20. ncbi request reprint A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes
    Richard J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, University of Arizona, 85259, USA
    Sleep 25:447-53. 2002
    ..To correlate memory measures with a trait measure of chronic daytime somnolence in cognitively normal individuals with different gene doses of the apolipoprotein E (APOE) e4 allele, a common Alzheimer's disease susceptibility gene...
  21. ncbi request reprint Progressive aphasia with Lewy bodies
    Richard J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, AZ 85259, USA
    Dement Geriatr Cogn Disord 14:55-8. 2002
    ....
  22. ncbi request reprint Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study
    R J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    J Neurol Sci 189:93-8. 2001
    ....
  23. pmc Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele
    Jessica B S Langbaum
    Banner Alzheimer s Institute, 901 E Willetta St, Phoenix, AZ 85006, USA
    Arch Neurol 67:462-8. 2010
    ....
  24. pmc Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology
    Winnie S Liang
    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Neurobiol Aging 31:549-66. 2010
    ..We also provide this high-quality, low post-mortem interval (PMI), cell-specific, and region-specific NDAD/AD reference data set to the community as a public resource...
  25. pmc Evidence for an association between KIBRA and late-onset Alzheimer's disease
    Jason J Corneveaux
    Translational Genomics Research Institute TGen, Neurogenomics Division, Phoenix, AZ 85004, USA
    Neurobiol Aging 31:901-9. 2010
    ..034; OR=1.29) and in a combined analysis of 1026 additional living and expired subjects (P=0.039; OR=1.26). Our findings suggest that KIBRA is associated with both individual variation in normal episodic memory and predisposition to AD...
  26. pmc Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging
    Eric M Reiman
    Banner Alzheimer s Institute and Banner Good Samaritan PET Center, 901 East Willetta Street, Phoenix, AZ 85006, USA
    Neuroimage 49:169-76. 2010
    ..We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD...
  27. ncbi request reprint Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates
    Kewei Chen
    Banner Alzheimer Institute, Banner Good Samaritan PET Center, 1111 E McDowell Rd, Phoenix, AZ 85006, USA
    Am J Psychiatry 164:916-21. 2007
    ..The authors previously found accelerated whole brain atrophy rates in patients with probable Alzheimer's disease by computing changes in brain volume from sequential magnetic resonance images (MRIs)...
  28. pmc Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism
    Eric M Reiman
    Positron Emission Tomography Center, Banner Good Samaritan Medical Center, Phoenix, AZ 85006, USA
    Proc Natl Acad Sci U S A 102:8299-302. 2005
    ..This study raises the possibility of using PET as a quantitative presymptomatic endophenotype to help evaluate the individual and aggregate effects of putative genetic and nongenetic modifiers of AD risk...
  29. pmc Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set
    Winnie S Liang
    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
    Physiol Genomics 33:240-56. 2008
    ..We provide this carefully phenotyped, laser capture microdissected intraindividual brain region expression data set to the community as a public resource...
  30. pmc Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain 131:2957-68. 2008
    ..There are several candidate outcome measures -- including the FTLD-CDR and the cognitive composites -- that could be used in clinical trials across the spectrum of FTLD...
  31. pmc Fibrillar amyloid correlates of preclinical cognitive decline
    Cynthia M Stonnington
    Department of Psychiatry and Psychology, Mayo Clinic in Arizona, Scottsdale, AZ, USA Electronic address
    Alzheimers Dement 10:e1-8. 2014
    ..It is not known whether preclinical cognitive decline is associated with fibrillar β-amyloid (Aβ) deposition irrespective of apolipoprotein E (APOE) ε4 status...
  32. pmc Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
    Eric M Reiman
    Positron Emission Tomography Center, Banner Good Samaritan Medical Center, Phoenix, AZ 85006, USA
    Proc Natl Acad Sci U S A 101:284-9. 2004
    ..Carriers of a common Alzheimer's susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia...
  33. pmc Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers
    Winnie S Liang
    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Neuroimage 54:1896-902. 2011
    ..It also supports the use of brain-imaging endophenotypes to help assess possible modifiers of AD risk...
  34. pmc Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions
    Eric M Reiman
    Banner Alzheimer s Institute and Banner Good Samaritan PET Center, Phoenix, AZ 85006, USA
    Neuroimage 40:1214-21. 2008
    ..The results support the role of cholesterol-related genes in the predisposition to AD and support the value of neuroimaging in the presymptomatic assessment of putative modifiers of AD risk...
  35. doi request reprint Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers
    Cynthia M Stonnington
    Division of Adult Psychiatry, Mayo Clinic, Scottsdale, AZ 85259, USA
    J Clin Psychiatry 70:1379-84. 2009
    ..To examine cognitive effects of pharmacologically induced somnolence in cognitively normal carriers and noncarriers of the apolipoprotein E (APOE)-epsilon4 allele, a common Alzheimer's disease susceptibility gene...
  36. pmc Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
    Eric M Reiman
    Banner Alzheimer s Institute and the Positron Emission Tomography Center, Good Samaritan Regional Medical Center, Phoenix, AZ 85006, USA
    Proc Natl Acad Sci U S A 106:6820-5. 2009
    ....
  37. ncbi request reprint Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study
    Dona E C Locke
    Department of Psychiatry and Psychology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259
    J Clin Psychiatry 74:1256-61. 2013
    ..To determine if symptoms of depression accelerate in cognitively normal apolipoprotein E (APOE) ε4 carriers as compared to noncarriers...
  38. pmc Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares
    Kewei Chen
    Banner Alzheimer s Institute and Banner Good Samaritan PET Center, Phoenix, AZ, USA
    Neuroimage 60:2316-22. 2012
    ..7 × 10(-4)). Our findings support the possibility of using the MMPLS to analyze complementary datasets from the same person in the presymptomatic detection and tracking of AD...
  39. pmc Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons
    Jessica B S Langbaum
    Banner Alzheimer s Institute, Phoenix, AZ 85006, USA
    Neurobiol Aging 33:827.e11-9. 2012
    ..These preliminary findings provide additional evidence that higher BP, likely a reflection of arterial stiffness, during late midlife may be associated with increased risk of presymptomatic AD...
  40. doi request reprint Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia
    Amy C Almaraz
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Neurologist 15:234-7. 2009
    ..Therefore, cholinesterase inhibitors might improve cognitive function in PDD. On the other hand, enhancing cholinergic function could plausibly worsen features of parkinsonism...
  41. pmc Assessment of patient and caregiver experiences of dementia-related symptoms: development of the Multidimensional Assessment of Neurodegenerative Symptoms questionnaire
    Dona E C Locke
    Division of Psychology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Dement Geriatr Cogn Disord 27:260-72. 2009
    ..To provide preliminary validation data on a self- or informant-report multidimensional questionnaire of symptoms associated with neurodegenerative disorders...
  42. pmc Correlates of quitting the Paced Auditory Serial Addition Test in cognitively normal older adults participating in a study of normal cognitive aging
    Dona E C Locke
    Department of Psychiatry and Psychology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    J Clin Exp Neuropsychol 33:937-43. 2011
    ..We encourage investigators involved in longitudinal studies to consider causes for missing data, especially when secondary to participant refusal...
  43. pmc Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration
    Po H Lu
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Dement Geriatr Cogn Disord 35:34-50. 2013
    ..Using magnetic resonance imaging (MRI), tensor-based morphometry (TBM) was used to determine distinct patterns of atrophy between these three clinical groups...
  44. ncbi request reprint Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease
    Leslie C Baxter
    Neuropsychology Neuroimaging Laboratory, Barrow Neurological Institute, St Joseph s Hospital and Medical Center, 222 W Thomas Rd, Suite 310, Phoenix, AZ 85013, USA
    Neurobiol Aging 24:947-52. 2003
    ..This suggests that longitudinal study of new learning is a sensitive measure for detecting early cognitive changes in at-risk individuals that precede the symptomatic onset of mild cognitive impairment and AD...
  45. doi request reprint Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic
    Gretchen E Schlosser Covell
    Department of Neurology, Division of Education Administration, Mayo Clinic, Scottsdale, AZ, USA
    Neurologist 18:426-9. 2012
    ..Most of these studies have been cross-sectional, and often look at patients already with dementia. This leaves uncertainty with regard to the temporal relationship of circadian disruption and cognitive decline...
  46. ncbi request reprint Apolipoprotein E and intellectual achievement
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    J Am Geriatr Soc 50:49-54. 2002
    ..To determine whether apolipoprotein E (apo E) genotype influences intellectual achievement in cognitively normal individuals...
  47. pmc Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions
    Christine M Burns
    Departments of Psychology, University of Arizona, Tucson, AZ, USA
    Neurology 80:1557-64. 2013
    ....
  48. pmc Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene
    Jon Valla
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ, USA
    J Alzheimers Dis 22:307-13. 2010
    ..This functional biomarker may prove useful in early detection and tracking of AD and indicates that mitochondrial mechanisms may contribute to the predisposition to AD before any evidence of amyloid or tau pathology...
  49. doi request reprint Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic
    Katherine C Riordan
    Department of Neurology, Mayo Clinic, Mayo Clinic Hospital, Phoenix, AZ 85054, USA
    Neurologist 17:121-3. 2011
    ..Evidence that the use of memantine in a patient already on cholinesterase inhibitor therapy can provide a clinically significant benefit is limited...
  50. pmc Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease
    Pengcheng Han
    From the Barrow Neurological Institute P H, L C B, J Y, Z T, J S, St Joseph Hospital and Medical Center, Dignity Health Organization, Phoenix Translational Genomics Research Institute W L, Phoenix, AZ Department of Neurosurgery Z T, The First Hospital of Kunming Medical University, Kunming, China Civin Laboratory for Neuropathology T G B, Banner Sun Health Research Institute, Sun City Department of Neurology R J C, Mayo Clinic Arizona, Scottsdale and Banner Alzheimer s Institute E M R, Phoenix, AZ
    Neurology 82:1724-8. 2014
    ..There is growing evidence that pituitary adenylate cyclase-activating polypeptide (PACAP) is associated with Alzheimer disease (AD) pathology in animal models, but human studies are needed...
  51. pmc GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers
    Eric M Reiman
    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
    Neuron 54:713-20. 2007
    ..Our findings suggest that GAB2 modifies LOAD risk in APOE epsilon4 carriers and influences Alzheimer's neuropathology...
  52. pmc Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults
    Gene E Alexander
    Department of Psychology, University of Arizona, Tucson, AZ 85721, USA
    Neurobiol Aging 33:2723-32. 2012
    ....
  53. pmc Linking functional and structural brain images with multivariate network analyses: a novel application of the partial least square method
    Kewei Chen
    Banner Alzheimer s Institute and the Banner Good Samaritan PET Center, Phoenix, AZ 85006, USA
    Neuroimage 47:602-10. 2009
    ....
  54. doi request reprint Anxiety affects cognition differently in healthy apolipoprotein E ε4 homozygotes and non-carriers
    Cynthia M Stonnington
    Dept of Psychiatry and Psychology, Section of Biostatistics, and Dept of Neurology, Mayo Clinic, Arizona, USA
    J Neuropsychiatry Clin Neurosci 23:294-9. 2011
    ..The association of executive-functioning difficulties and anxiety appears more likely to occur in persons who are most at risk for subsequent cognitive decline...
  55. pmc APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
    Andrew B Wolf
    Department of Biochemistry, Midwestern University, Glendale, AZ, USA
    Neurobiol Aging 34:1007-17. 2013
    ..This research might lead to the identification of novel therapeutic targets for the treatment and/or prevention of Alzheimer's disease...
  56. pmc Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases
    Giovanni Coppola
    Department of Neurology, University of California, Los Angeles, CA, USA
    Hum Mol Genet 21:3500-12. 2012
    ....
  57. pmc Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments
    Eric M Reiman
    Banner Alzheimer s Institute, Phoenix, AZ 85006, USA
    J Alzheimers Dis 26:321-9. 2011
    ....
  58. pmc Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: a case series
    Farrah J Mateen
    Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
    Neurocase 18:1-12. 2012
    ..Clinicopathological studies of non-vasculitic steroid-responsive encephalopathy are unusual, but can explain the range of diagnoses consistent with a steroid-responsive presentation in life...
  59. pmc Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination
    Reem F Bunyan
    Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Arch Neurol 68:525-8. 2011
    ..To describe a case of childhood-onset progressive multiple sclerosis with dementia and evidence of extensive cortical demyelination from brain biopsy specimen...
  60. ncbi request reprint Current issues in the diagnosis and management of dementia
    Richard J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Semin Neurol 23:231-40. 2003
    ..Mild cognitive impairment, topography and semiology of dementia syndromes, reversible forms of dementia, dementia therapy, driving, genetic testing of patients and family members, and caregiver risk are reviewed...
  61. ncbi request reprint Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy
    D F Tang-Wai
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 63:1168-74. 2004
    ..To examine the clinical, genetic, and neuropathologic features of posterior cortical atrophy (PCA)...
  62. ncbi request reprint Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations
    John N Caviness
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Mov Disord 17:657-62. 2002
    ..Although the myoclonus occurred without dementia in these cases, its relationship to the subsequent development of cognitive impairment remains to be defined...
  63. ncbi request reprint Longitudinal tracking of FTLD: toward developing clinical trial methodology
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Alzheimer Dis Assoc Disord 21:S58-63. 2007
    ..In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored...
  64. pmc Off-label medication use in frontotemporal dementia
    - Bei Hu
    Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
    Am J Alzheimers Dis Other Demen 25:128-33. 2010
    ..We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics...
  65. ncbi request reprint Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases
    Mark K Lyons
    Department of Neurological Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    J Neurosurg 108:1024-7. 2008
    ..This procedure is important because NAIM can be treated successfully if it is distinguished from the nontreatable dementias that mimic it...
  66. ncbi request reprint "Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases
    Mark G Hickey
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:98-101. 2007
    ..To determine whether a diagnosis of idiopathic rapid-eye-movement sleep behavior disorder (RBD) is associated with a future risk of development of neurodegenerative diseases...
  67. ncbi request reprint Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease
    C Hoffman Snyder
    Department of Neurology, Mayo Clinic Arizona, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Arch Neurol 63:766-8. 2006
    ....
  68. ncbi request reprint Electrophysiology of the myoclonus in dementia with Lewy bodies
    J N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
    Neurology 60:523-4. 2003
  69. ncbi request reprint Motor unit number estimates in idiopathic Parkinson's disease
    J N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 8:161-4. 2002
    ..Progress in decreasing the variance of MUNEs will facilitate their use in detecting small motor unit number changes in neurodegenerative disease...
  70. pmc Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1843-9. 2009
    ..Because there is only limited longitudinal imaging data currently available, we measured the rate of change over 1 year of whole brain volume (WBV) and ventricular volume (VV) in patients with FTLD...
  71. ncbi request reprint Corticobasal degeneration and frontotemporal dementia presentations in a kindred with nonspecific histopathology
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Dement Geriatr Cogn Disord 13:80-90. 2002
    ....
  72. pmc Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia
    Rosa Rademakers
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL FL 32224, USA
    Hum Mol Genet 17:3631-42. 2008
    ..Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders...
  73. pmc Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype
    Nicola J Rutherford
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Neurobiol Aging 33:2950.e5-7. 2012
    ..No meaningful association between the repeat length of the normal alleles of the GGGGCC repeat in C9ORF72 and disease phenotype or age at onset was observed in C9ORF72 mutation carriers or nonmutation carriers...
  74. pmc Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
    Winnie S Liang
    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Physiol Genomics 28:311-22. 2007
    ..These neuronal profiles will provide valuable reference information for future studies of the brain, in normal aging, AD and other neurological and psychiatric disorders...
  75. doi request reprint Autoimmune encephalopathy
    Eoin P Flanagan
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Semin Neurol 31:144-57. 2011
    ..Paraneoplastic syndromes typically require tumor removal and often prove fatal. CNS vasculitides may respond to steroid therapy, but often require a second agent such as cyclophosphamide...
  76. doi request reprint Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients
    Sara L P Schrader
    Department of Neurology, Division of Education Administration, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Neurologist 14:134-7. 2008
    ..More effective preventive strategies could notably impact morbidity, mortality, and health care costs...
  77. ncbi request reprint Myoclonus in Lewy body disorders
    John N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Adv Neurol 89:23-30. 2002
  78. pmc Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
    E M Reiman
    Department of Psychiatry, University of Arizona, Tucson, AZ 85724, USA
    Proc Natl Acad Sci U S A 98:3334-9. 2001
    ....
  79. ncbi request reprint The treatable dementia of Sjögren's syndrome
    R J Caselli
    Department of Neurology, Mayo Clinic, Rochester, MN
    Ann Neurol 30:98-101. 1991
    ..Treatment with high-dose corticosteroids produced rapid and nearly complete resolution of the dementia...
  80. ncbi request reprint Giant cell arteritis
    Todd J Schwedt
    Washington University School of Medicine, Department of Neurology, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO 63110, USA
    Curr Pain Headache Rep 10:415-20. 2006
    ..Prompt treatment with corticosteroids is essential in order to minimize the frequency of permanent sequelae such as visual loss and stroke...
  81. ncbi request reprint Alzheimer's disease
    E M Reiman
    Department of Psychiatry, University of Arizona, Tucson, USA
    Maturitas 31:185-200. 1999
    ....
  82. ncbi request reprint Current epidemiology of mild cognitive impairment and other predementia syndromes
    Francesco Panza
    Dept of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy
    Am J Geriatr Psychiatry 13:633-44. 2005
    ..To clarify the sources of discrepant findings in the literature, this review summarizes existing epidemiological studies of the defined clinical predementia syndromes and their progression to dementia...
  83. ncbi request reprint Cognitive frailty: Predementia syndrome and vascular risk factors
    Francesco Panza
    Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy
    Neurobiol Aging 27:933-40. 2006
    ..This review will focus on the possible role of vascular risk factors in modulating the risk of age-related cognitive decline, and the progression of predementia syndrome such as MCI to dementia...
  84. ncbi request reprint Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment
    Sterling C Johnson
    Geriatric Research Education and Clinical Center, Wm S Middleton VA Hospital, Madison, WI 53705, USA
    Neuropsychologia 42:980-9. 2004
    ..Results suggest that the medial temporal response over repeated presentation is related to clinical status. Probes of incremental encoding processes over trials may be useful markers of medial temporal lobe integrity...
  85. ncbi request reprint Regional network of magnetic resonance imaging gray matter volume in healthy aging
    Gene E Alexander
    Neuroimage Analysis Laboratory, Department of Psychology, Arizona State University, Tempe, AZ 85287 1104, USA
    Neuroreport 17:951-6. 2006
    ..Scaled Subprofile Model network analysis may aid in the detection and tracking of brain aging and in the evaluation of putative antiaging therapies...
  86. ncbi request reprint Common Kibra alleles are associated with human memory performance
    Andreas Papassotiropoulos
    Division of Psychiatry Research, University of Zurich, Zurich 8057, Switzerland
    Science 314:475-8. 2006
    ..Functional magnetic resonance imaging detected KIBRA allele-dependent differences in hippocampal activations during memory retrieval. Evidence from these experiments suggests a role for KIBRA in human memory...
  87. ncbi request reprint Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness
    Jennifer L Etnier
    Department of Exercise and Sport Science, University of North Carolina, Greensboro, NC 27402, USA
    Med Sci Sports Exerc 39:199-207. 2007
    ..Apolipoprotein E (ApoE) genotype and aerobic fitness are each associated with cognitive performance in older adults. However, their potentially interactive effects on cognitive performance have not been examined...
  88. doi request reprint Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging
    Francesco Panza
    Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy
    Dement Geriatr Cogn Disord 25:336-46. 2008
    ..We evaluated the impact of depressive symptoms on the rate of incident mild cognitive impairment (MCI) after a 3.5-year follow-up, and we assessed the interaction between depressive symptoms and vascular risk factors for incident MCI...
  89. ncbi request reprint Incident occurrence of depressive symptoms among patients with mild cognitive impairment - the Italian longitudinal study on aging
    Vincenzo Solfrizzi
    Memory Unit, Center for Aging Brain, Department of Geriatrics, University of Bari, Bari, Italy
    Dement Geriatr Cogn Disord 24:55-64. 2007
    ..We estimated the prevalence and incidence rates of depressive symptoms and the role of vascular risk factors and sociodemographic variables on the occurrence of depressive symptoms in mild cognitive impairment (MCI)...
  90. pmc Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis
    Nicola J Rutherford
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS Genet 4:e1000193. 2008
    ....
  91. pmc Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms
    Stacey Melquist
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Am J Hum Genet 80:769-78. 2007
    ..Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease...
  92. ncbi request reprint Cognitive impairment, frontotemporal dementia, and the motor neuron diseases
    Michael J Strong
    Department of Clinical Neurological Sciences and the Robarts Research Institute, London, Ontario, Canada
    Ann Neurol 54:S20-3. 2003
  93. ncbi request reprint January 16 highlight and commentary: subspecialization within somatosensory cortex
    Richard J Caselli
    Neurology 68:1955; author reply 1955-6. 2007
  94. ncbi request reprint Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects
    Douglas A Hinerfeld
    Arch Neurol 64:1672-3. 2007